A JAMA case report connected extensive amyloid removal after amyloid-targeting therapies with subsequent reductions in neuropathologic changes in Alzheimer’s disease. The study suggests a measurable relationship between amyloid burden reduction and downstream disease progression markers. Researchers observed that areas showing more complete amyloid clearance correlated with fewer later neuropathologic changes, supporting the idea that amyloid-targeting effects may translate into downstream pathology suppression. The report is based on detailed clinicopathologic observation following amyloid-targeted intervention. For drug developers and biomarker teams, the value is direct tissue-based linkage between clearance patterns and pathology evolution, which can inform how efficacy is assessed in future Alzheimer’s trials and translational studies.